Blog

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Photo from Nathan A. Pennell/X

Jan 13, 2024, 10:04

Nathan A. Pennell: Pralsetinib development outside the US and China also stopped

Nathan A. Pennell, Co-Director of the Cleveland Clinic Lung Cancer Program, shared a post by EGFR Resisters on X/Twitter:

“Oh man, pralsetinib (for RET+ tumors) development outside the US and China also stopped. Hope this gets resumed with new partners.”

Quoting EGFR Resisters’s post:

“Blueprint Medicines issued press release: “Discontinue further investment in the early clinical stage therapies BLU 945 and 451 for EGFR Non-Small Cell Lung Cancer and explore strategic options including potential outlicensing” Blu-945 and Blu-451 clinical trials will close.”

Read further.

Source: Nathan A. Pennell/X and EGFR Resisters/X

Blu-451 Blu-945 Blueprint Medicines cancer Cleveland Clinic EGFR Resisters Nathan A.Pennell non small cell lung cancer NSCLC OncoDaily Oncology pralsetinib RET

Esophageal Cancer: Symptoms, Causes, Stages, Diagnosis & Treatment

Faster, Flexible and Affordable: Mikhail Groubman on Building a Global Legacy in Clinical Research in an Untapped Market

Invest in Health Policy: A Conversation with Professor Andreas Charalambous

FDA Approves Cosibelimab-ipdl for Treatment of Metastatic or Locally Advanced Cutaneous Squamous Cell Carcinoma

Dolph Lundgren’s Fight for Life: How He Survived Kidney Cancer After 9 Years of Battle

Special Coverage